Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-116

It was only part of the recent flu season, not the entire season and first release of the product in the US. The revenue in a quarter was $700,000USD.

The entire of the previous year was $300,00USD, which means in a quarter, in effect doubled revenue. Wait until the half yearly before determining product sales are not substantial. If we see annual revenue of $2Million then it is on track with Covid sales.

I think a number of people look at the sales generated through Covid and compare to now and think, oh crap, sinking shit. This isn't correct!

People should be looking at the Covid sales and think, BANG! Onto a bread winner. The revenue generated through Covid can be replicated here via Viradx and Febridx.

Covidx was ceased. You could attribute that to the fact Viradx performs the same task. Why produce 2 products when there is an all in one?

CLIA waiver will be a big game changer in what this can achieve, but recalling Doug's mindset of under promise and overachieve, the time frame could be cut down. Given the sheer number of trials Febridx has gone through and continues to go through, there may be a shortened time frame to receiving it. Sam Lanyon made comment in the ****** interview: "And the US is a really great example of that. And, uh, and last year we did actually get our 510 K approval. Um, and we're looking to add to that, uh, in the coming sort of 6 to 12 months." Maybe this is expansion of region or, 510K for Viradx? Or CLIA Waiver? Or something else?

We need to see both Viradx and Febridx distributed in Australia. When the US/UK flu season ends, the AUS flu season begins, means yearly potential sales of the product.